NLS Pharmaceutics (Nasdaq: NLSP) and Kadimastem (TASE: KDST) have reached a key milestone in their planned merger after Kadimastem’s shareholders approved the deal in a special general meeting. The merger aims to create a Nasdaq-listed biotechnology company with a strong portfolio of treatments for neurodegenerative diseases and diabetes. NLS is now preparing to hold its […]